Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$80.48 USD

80.48
2,626,827

-0.68 (-0.84%)

Updated Sep 11, 2024 03:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (30 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer's Drug Combo Betters Survival in Kidney Cancer Study

Pfizer's (PFE) phase III study on a combination of its cancer drugs, Bavencio and Inlyta meets primary endpoint of improving PFS in advanced kidney cancer patients with PD-L1+ tumors.

    The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

    The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

      Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus

      Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.

        AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status

        AstraZeneca (AZN) and partner Amgen's asthma candidate, tezepelumab gets Breakthrough Therapy designation from the FDA.

          AstraZeneca Up This Year So Far on Favorable Pipeline Updates

          AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

            AstraZeneca's Lupus Drug Misses Primary Endpoint in Study

            AstraZeneca's (AZN) phase III study, evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus, does not meet primary endpoint.

              Kinjel Shah headshot

              4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline

              We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.

                Bausch (BHC) Resubmits NDA for Duobrii for Plaque Psoriasis

                Bausch Health Companies Inc. (BHC) resubmits its NDA for plaque psoriasis drug, Duobrii to the FDA and the agency has set a PDUFA action date of Feb 15, 2019.

                  AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon

                  AstraZeneca (AZN) gains EU approval for a new formulation of its diabetes medicine Bydureon ??? Bydureon BCise.

                    Zacks.com headshot

                    Bausch (BHC) Gets FDA Approval for Altreno for Acne Vulgaris

                    Bausch (BHC) advances its dermatology portfolio with the FDA approval of Altreno for acne vulgaris.

                      Merck, Eisai Get EU Approval for Lenvima Label Expansion

                      Merck (MRK) and Japanese partner Eisai gain an approval from the EU for Lenvima label expansion. The anti-cancer drug receives the regulatory body's nod for first-line treatment of unresectable HCC.

                        AstraZeneca's Bevespi Unimpressive in Phase III COPD Study

                        AstraZeneca's (AZN) inhaler, Bevespi Aerosphere, fails to demonstrate superiority over Glaxo's Arono in a phase III COPD study.

                          Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs

                          Allergan (AGN) gets CRL for uterine fibroids candidate, Esmya. Merck (MRK) and Bristol-Myers' (BMY) PD-L1 inhibitors get FDA approval for expanded labels.

                            Novartis Breast Cancer Drug Meets Primary Goal in Phase III

                            Novartis' (NVS) late-stage candidate, BYL719, meets primary endpoint in SOLAR trial on advanced breast cancer patients.

                              Ironwood's Linzess Gets Approval in Japan for New Indication

                              Ironwood Pharmaceuticals (IRWD) along with its partner Astellas Pharma announces approval of Linzess in Japan for a new indication - chronic constipation.

                                Japan Nods to AstraZeneca's Tagrisso for First-Line NSCLC

                                AstraZeneca (AZN) receives approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the label expansion of Tagrisso.

                                  Merck, Eisai Get FDA Approval for Lenvima Label Expansion

                                  Merck (MRK) and Japanese partner Eisai gains an FDA approval for Lenvima label expansion. The anti-cancer drug receives the regulatory body's nod for the first line treatment of unresectable HCC.

                                    Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication

                                    Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.

                                      Mark Vickery headshot

                                      Top Research Reports for Cisco, AstraZeneca & Enbridge

                                      Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems (CSCO), AstraZeneca (AZN) and Enbridge (ENB).

                                        Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

                                        Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.

                                          Here's Why Merck (MRK) Stock is Up Since Q2 Earnings Release

                                          Merck's (MRK) stock is up 4.2% since announcement of earnings in July. Let us have a look at the reasons for the same.

                                            The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

                                            The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

                                              Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

                                              Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.

                                                What's in the Cards for Perrigo (PRGO) This Earnings Season?

                                                Perrigo's (PRGO) product purchases and introductions in the Rx segment are expected to boost sales.

                                                  Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down

                                                  Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.